News related to
Stage

World-First Innovations Showcase Hong Kong’s Thriving Life and Health Tech Ecosystem from Bench to Bedside

HONG KONG SAR – Media OutReach Newswire – 12 May 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP) joined alongside 38 Park companies in the two flagship events of the 5^th International Healthcare Week — the Hong Kong International Medical and Healthcare Fair (“Medical Fair”) and the Asia Summit on Global Health (“ASGH”), held from 11 – 13 May. Showcasing at these premier medical innovation and technology (I&T) events, HKSTP is demonstrating its pivotal role in nurturing and supporting the growth of biotechnology enterprises. During ASGH, HKSTP also hosted a dedicated investor pitch session, providing Park companies with an exclusive stage to connect directly with global capital and pursue fundraising opportunities.

Over 30 Market-Ready Solutions across Four Key Industry Focus

On the opening day of the Medical Fair, the HKSTP pavilion drew numerous industry professionals, investors and professional buyers, who gathered to explore Hong Kong’s latest I&T achievements and actively discuss collaboration opportunities. Participating companies span four critical areas — health monitoring, surgical assistance, precision medicine, rehabilitation training — comprehensively demonstrating the diverse strengths of Hong Kong’s life and health technology sector as it progresses from research and development (R&D) to commercial application.

Mr Terry Wong, CEO of HKSTP, said: “HKSTP has always been a steadfast partner to tech ventures, building a vibrant and well-established ecosystem for biotech companies ranging from start-ups with early-stage innovation to experienced innovators with market-ready solutions. To meet their diverse needs, we offer end-to-end support from R&D to clinical applications, including lab facilities, funding connections and market expansion. Our presence at this event fully reflects the innovative vitality and strength of Hong Kong’s life and health tech ecosystem. We hope to showcase Hong Kong’s cutting-edge medical R&D achievements to the international community, while delivering a clear message: Hong Kong is not only a top-tier scientific research base, but also the strongest springboard for technology enterprises to go global. By uniting forces across all sectors, we will further solidify Hong Kong’s leadership as an international health tech hub.”

Park company Highlights:

• Endovision offers an intestinal endoscopic imaging system that leverages AI and real-time imaging to assist physicians in conducting more precise examinations. The solution has already obtained EU Medical Device Regulation (MDR) certification.
• Mirror Caring presents SyncKnee, a smart wearable solution integrating flexible sensors, embedded systems and AI analytics to deliver real-time monitoring of knee joint health and data-driven insights.
• Voice Empowerment Technology features a customised “AI Voice Reconstruction Tool” designed to enhance the efficiency of speech therapy services, offering breakthrough communication support for patients with aphasia and speech disorders.

“World-First” Cutting-Edge Medical Technologies Take Centre Stage

This year, HKSTP has also set up a dedicated exhibition zone at the Asia Summit on Global Health (ASGH), spotlighting a range of groundbreaking biomedical solutions, including several “world-first” innovations:

• Agilis Robotics: The world’s first robotic-assisted “En Bloc Transurethral Resection of Bladder Tumour”, achieving precise tumour resection margins and offering a minimally invasive surgical option with faster recovery for early-stage cancer patients.
• GenEditBio: The world’s first in vivo genome editing therapy (often referred to as “DNA surgery”) targeting corneal dystrophy, with Phase I clinical trials expected to commence this year, aiming to improve patients’ quality of life.
• Meta Pharmaceuticals: The world’s first oral inhibitor for treating autoimmune diseases such as inflammatory bowel disease and multiple sclerosis, enhancing medication convenience and delivering safer, more effective anti-inflammatory therapy.

Dedicated Investor Pitch Session: Connecting Global Capital to Accelerate Enterprise Growth

For early-stage biotech companies, funding is crucial to sustaining research and achieving breakthroughs. To this end, HKSTP is fulfilling its role as a “super-connector” by hosting the “Life and Health Technology Innovation Pitch” at ASGH, to bridge between Park companies and the global market and deepen international partnerships.

The pitch session bought together 12 leading global investors from the UK, the US, Singapore, Canada and beyond, creating a top-tier platform for fundraising and business matching, and accelerating the translation of life and health tech innovations. Ten Park companies with breakthrough technologies took the stage to attract international capital, further showcase their innovative solutions and advance to the next stage of growth and global expansion.

Event Details:
Hong Kong International Medical and Healthcare Fair (Medical Fair)
Date: 11–13 May 2026
Venue: Hong Kong Convention and Exhibition Centre, Hall 3DE
HKSTP Booth: 3E-E06

Asia Summit on Global Health (ASGH)
Date: 11–12 May 2026
Venue: Hong Kong Convention and Exhibition Centre, Hall 3FG
HKSTP Booth: 3F-A11
Hashtag: #HKSTP

The issuer is solely responsible for the content of this announcement.

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 17,000 research professionals and over 2,500 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at www.hkstp.org.

Securing Maryland-Based Drug-Substance Facility and Existing Commercial Orders to Scale the Group’s Integrated Technology Platform

HONG KONG SAR – Media OutReach Newswire – 12 May 2026 – Bora Pharmaceuticals (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY) today announced that its Board of Directors has approved the acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, subject to customary working capital adjustments, and a contingent consideration of up to $5 million based on future customer orders. The transaction includes a biologics drug substance manufacturing facility located in Rockville, Maryland and an associated warehousing center in Frederick, Maryland. Upon closing of the acquisition, the Company will sign a long-term CDMO Service Agreement with MacroGenics.

Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to scale the Group’s end-to-end biologics platform.

The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA. From the transaction, Bora is expected to assume a substantial backlog for the size of its Bora Biologics CDMO business, including commercial-stage monoclonal antibody programs, clinical-stage programs, and a strong project pipeline. Commercial manufacturing currently accounts for more than half of the site’s revenue.

“This acquisition marks a pivotal step in strengthening Bora’s integrated biologics CDMO platform in the United States”, said Bobby Sheng, Chairman and CEO of Bora Group. “With the addition of the Rockville site, Bora Biologics total drug substance capacity would be 20,000-liter (SUB) and Bora Group will integrate our in-house DS (Drug Substance) and DP (Drug Product) capabilities and network investments over the next 12 to 18 months to offer global biotech customers a seamless offering allowing customers to advance programs from development through commercial supply with one single partner.”

Bora’s Board of Directors has authorized the Chairman to finalize the transaction in line with market conditions and the regulatory environment. For the year ended December 31, 2025, MacroGenics reported contract manufacturing revenue of $52.6 million.
Hashtag: #BoraPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

Short Courses Structured for Busy Professionals

For working adults who want targeted upskilling, SIM Academy’s course listing includes instructor-led programmes that are typically offered in short formats. The 1-day or 2-day course structure may appeal to professionals seeking to build capability while balancing work and personal commitments.

The topics covered reflect a mix of core workplace capabilities and emerging skill areas, including communication skills, cognitive skills, systems leadership, sustainability, as well as broader organisational and leadership competencies. Such short-format training has become a common feature within Singapore’s continuing education landscape, particularly among working adults seeking to remain competitive in a changing job market.

SkillsFuture Funded Training Courses

A number of SIM Academy’s professional development courses are eligible for SkillsFuture Credit and related funding schemes. These funding mechanisms are part of national efforts to encourage lifelong learning and support workforce transformation. The availability of funding-supported courses may lower barriers to participation for individuals and employers, particularly for those pursuing incremental skills upgrading.

Career Switch for mid‑career professionals

SIM Academy offers programmes under the SkillsFuture Career Transition Programme (SCTP). These programmes are designed for individuals considering a shift into new roles or sectors and typically run over 5-6 months. Programme structures may include a combination of classroom learning, practical projects and career support elements such as guidance on job search and career planning.

This reflects a broader trend in Singapore’s training ecosystem, where structured transition programmes are increasingly used to support workforce mobility and adaptation to new job roles.

Flexible Delivery Formats

SIM Academy’s programmes are delivered through a mix of in-person, online and blended learning formats. This allows participants to select learning modes that align with their schedules and professional commitments. Short courses are conducted throughout the year, primarily at SIM Management House, alongside digital learning options that support greater accessibility. Flexible delivery has become an increasingly important feature of professional education, particularly for working adults balancing training with full-time employment.

Part of a Broader Continuing Education Landscape

As industries continue to evolve, demand for continuous skills development remains a key focus within Singapore’s workforce strategy. Short courses, modular training and structured transition programmes are among the approaches adopted by training providers to meet these needs.

SIM Academy’s range of offerings includes shorter, skills-focused workshops and longer-duration programmes designed to support career transitions.

References

• SIM Academy: https://www.sim.edu.sg/professional-development/overview
• Courses offered by SIM Academy: https://www.sim.edu.sg/professional-development/courses/course-listing
• SkillsFuture Courses offered at SIM: https://www.sim.edu.sg/professional-development/courses/skillsfuture-courses
• SkillsFuture Career Transition Programme (SCTP): https://sctp.pd.sim.edu.sg

Hashtag: #SIMAcademy #SIMA

https://www.sim.edu.sg/

The issuer is solely responsible for the content of this announcement.

About SIM Academy

SIM Academy provides leading-edge professional development and enterprise solutions. SIM Academy offers over 300 executive and business programmes that help almost 10,000 professionals annually on average hone their competencies to drive business value and achieve peak personal and enterprise performance.

Our programmes encompass a comprehensive range of lifelong learning opportunities designed to empower professionals with the knowledge, skills, and competencies necessary to become effective change-makers and leaders in today’s volatile and uncertain business landscape.

For more information on SIM Academy, visit sim.edu.sg

The revised plan would involve the sale of a 2.5 per cent stake through new shares, with the proceeds flowing to Jio Platforms rather than to shareholders seeking exits. The change marks a significant adjustment in what is expected to be one of the largest public offerings in the country’s capital markets, and places long-term growth funding ahead of partial monetisation by early backers.

Jio Platforms, controlled by Mukesh Ambani’s Reliance Industries, owns Reliance Jio Infocomm and houses a broad portfolio of digital services spanning telecom, broadband, cloud, media, payments and consumer technology platforms. Its shareholder base includes Meta, Google, Vista Equity Partners, KKR, Mubadala, Abu Dhabi Investment Authority and Saudi Arabia’s Public Investment Fund, many of which entered the company during the 2020 fundraising cycle.

Earlier discussions had explored an offer-for-sale structure under which foreign investors could have sold about 8 per cent of their individual holdings, amounting to roughly 2.5 per cent of Jio Platforms. That approach has now been set aside, with investors opting to remain exposed to the business rather than reduce stakes at the listing stage.

The decision strengthens Reliance’s control over the IPO narrative. A fresh issue allows the company to present the listing as a growth-financing event instead of an exit window for private investors. It also limits the risk that the market interprets selling by marquee shareholders as a signal of valuation caution, particularly at a time when global technology listings are being judged closely on profitability, cash generation and regulatory exposure.

Jio Platforms is widely seen as the centrepiece of Reliance Industries’ transition from an energy-heavy conglomerate to a broader consumer, digital and technology group. The telecom arm has become one of the world’s largest mobile operators by users, while its digital ecosystem has helped Reliance build links across retail, entertainment, finance and enterprise services.

The company’s operating performance has supported expectations of a high-profile listing. Jio Platforms reported strong profit growth for the quarter ended March 2026, helped by tariff-led gains, subscriber additions, higher data consumption and expansion in home broadband. Average revenue per user rose to ₹214, reflecting improved monetisation after tariff increases and a better customer mix.

The proposed IPO has been closely watched since Ambani told shareholders that Jio Platforms was being readied for a market debut in the first half of 2026. Preparations gathered pace after listing rules were adjusted to make it easier for very large companies to float a smaller portion of equity while still meeting public-shareholding requirements over time.

A 2.5 per cent offering would keep public float modest at the start, but even that limited stake could translate into a multibillion-dollar transaction if the company commands a valuation close to estimates that have placed Jio Platforms around $180 billion. At that level, the IPO could rank among the largest listings ever seen on domestic exchanges.

The timing remains sensitive. Equity markets have been volatile as investors weigh interest-rate expectations, geopolitical risks, technology valuations and capital flows into emerging markets. Several large companies have adjusted listing timetables as issuers and bankers test demand from institutional and retail investors.

Reliance has assembled a large banking syndicate for the transaction, underlining the scale and complexity of the planned sale. The deal will require careful pricing to balance investor appetite, Reliance’s valuation expectations and the interests of existing shareholders who invested at a premium during the digital fundraising boom.

For Meta and Google, continued ownership preserves access to one of the world’s largest digital consumer markets through partnerships linked to messaging, cloud services, devices and online commerce. For sovereign wealth funds and private equity investors, remaining invested offers exposure to a mature telecom platform with rising cash flows and expanding digital adjacencies.

The IPO will also have implications for Reliance Industries’ own market valuation. Investors have long debated whether separate listings of Jio Platforms and Reliance Retail could unlock value trapped inside the conglomerate structure. A successful Jio debut may narrow the holding-company discount, while a weak listing would raise questions over the pace and pricing of Reliance’s broader demerger and monetisation strategy.

Richard Cheng, Associate Commercial Director (Hong Kong & Macau) at BeOne, said: “We are honored to receive this award from the Hong Kong Commercial Times. BeOne has built differentiated capabilities across clinical development and manufacturing, supported by a broad and diverse R&D pipeline. In Hong Kong, we have introduced several therapies, including BTK, PD-1 and IL-6 inhibitors. Looking ahead, we will continue to advance our plans in Hong Kong by leveraging opportunities enabled by the ‘1+’ policy and the planned establishment of the Hong Kong Centre for Medical Products Regulation (CMPR) and its ‘primary evaluation’ mechanism. Supported by our global supply network, we aim to bring additional medicines to patients in Hong Kong and the Greater Bay Area and help improve access to treatments aligned with international standards.”

Global R&D and Innovation

Founded in 2010, BeOne is focused on accelerating key stages of oncology innovation—from discovery through development to patient access. Through an integrated model spanning R&D, manufacturing and commercialization, the company works to translate innovation into clinical value. Today, BeOne operates across six continents in more than 45 markets and is supported by more than 1,200 oncology R&D professionals.

BeOne’s R&D platform has advanced more than 35 clinical-stage drug candidates, including three internally developed products that have received commercial approval, reaching more than 2 million patients worldwide.

Pipeline Highlights

BeOne continues to expand its global footprint through a portfolio of internally developed products, including:

• BTK Inhibitor: As the company’s first self-developed innovative drug, it holds a significant position in the global market (including Hong Kong), particularly in the field of B-cell malignancies.
• PD-1 Inhibitor: Launched in more than 50 markets worldwide, reaching 1.8 million people. In Hong Kong, it has been approved for six indications, including immunotherapy for lung, esophageal and gastric cancers.
• Next-Generation BCL-2 Inhibitor: Approved for certain lymphoma indications in Mainland China. It has been granted Priority Review by the U.S. Food and Drug Administration, and a marketing application has been submitted in the European Union.

Manufacturing Network Supporting Global Supply

BeOne maintains an integrated chain from R&D to manufacturing and commercialization, supported by production sites in the United States and China designed to help maintain a stable global supply:

• New Jersey, U.S.: A North America biologics hub integrating manufacturing and clinical R&D. The site spans 1.82 million square feet, including a dedicated 400,000-square-foot production facility.
• Suzhou, China (small molecule manufacturing): Supports clinical and commercial-scale production in accordance with applicable FDA, EMA and GMP requirements.
• Guangzhou, China (biologics and ADC manufacturing): A 1.3 million-square-foot facility supporting R&D and production of antibody-drug conjugates (ADCs) and serving as a supply hub for the Greater Bay Area, including Hong Kong.

BeOne has also been recognized by industry organizations for its innovation, including being named one of the “Top 10 Most Inventive” pharmaceutical companies by IDEA Pharma in 2025^[1]. The company will continue to advance programs in hematologic malignancies and solid tumors, with Hong Kong serving as a strategic hub to support the delivery of innovative therapies globally.

1. 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma

This material is intended for the purpose of communicating disease-related knowledge and cutting-edge medical information to the public and is not intended for promotional or advertising purposes. It does not constitute a promotion or recommendation for any medication or treatment plan, nor can it serve as a substitute for the advice of medical and health professionals. If you have any questions, please consult a medical or health professional.

Hashtag: #BeOneMedicines

https://www.beonemedicines.com/

The issuer is solely responsible for the content of this announcement.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland, focused on discovering and developing innovative treatments designed to be more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is advancing a diverse pipeline of novel therapeutics through internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to improving access to medicines for more patients. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

About HKCT Business Awards 2026

Organized by the Hong Kong Commercial Times, the HKCT Business Awards is a representative annual event in the Hong Kong business community. It honors companies demonstrating excellence, innovation, and significant contributions to Hong Kong’s economy and society across dimensions including technological innovation and market competitiveness.

Partnership pairs international leading longevity institution with HSBC’ to build the region’s first integrated “health and wealth” ecosystem for high‑net‑worth families.

HONG KONG SAR – Media OutReach Newswire – 11 May 2026 – Humansa, international leading integrated longevity institution and a premier destination for preventative healthcare, today announced the signing of a landmark Memorandum of Understanding (MoU) with The Hongkong and Shanghai Banking Corporation Limited (HSBC) and HSBC Life (International) Limited. This strategic collaboration aims to integrate advanced health optimisation with financial and insurance services, redefining how clients manage both their healthspan in Hong Kong and across the region.

A unified vision: healthspan as a core family asset

In a city renowned for its financial sophistication, the HSBC x Humansa alliance introduces a new paradigm: treating healthspan as a critical component of the modern family portfolio. As longevity science advances and demand for preventative healthcare accelerates, the partnership establishes a pioneering framework for an integrated “health and wealth” ecosystem designed specifically for high‑net‑worth and ultra‑high‑net‑worth clients.

Research from the Stanford Center on Longevity and other leading institutions highlights that many people in developed markets may live close to 100 years, making sustained cognitive and physical performance essential for a life of purpose and fulfilment. Simultaneously, global wealth reports show that affluent families are shifting spending from status goods toward wellness and longevity, and expect their financial partners to support this transition.

Moving beyond siloed services that treat health, wealth and insurance separately, Humansa contributes clinical excellence and geroscience‑based, data‑driven insights, while HSBC brings its wealth and insurance capabilities and a long‑term commitment to Asia as the world’s next major cross‑border wealth hub. Together, the parties aim to build the specialised infrastructure needed to manage health as a high‑value, appreciating asset over a 100‑year life.

Research‑driven excellence for high‑net‑worth clients

Humansa will lead the exploration of specialised longevity programs and dedicated physical spaces that combine clinical precision, behavioural coaching, and premium client experiences tailored to HSBC’s clients. By merging Humansa’s geroscience expertise with HSBC’s global wealth management reach and HSBC Life’s insurance capabilities, the partnership seeks to ensure that clients living longer – and better, at every stage of life.

Directives of the strategic collaboration: three pillars of “Longevity as an Asset”

Under the terms of the MoU, the parties have committed to three key pillars:

Longevity hubs and programs for HSBC clients – Explore the development of flagship “Longevity as an Asset” hubs and programs, where HSBC high-net-worth clients can access Humansa’s advanced diagnostics, health assessments and geroscience‑based services designed to preserve and grow their healthspan capital.

Integrated health‑wealth and insurance advisory – Pilot models where Humansa’s health insights can complement HSBC’s wealth and HSBC Life’s insurance advisory, enabling clients to align wealth management protection and succession strategies with their projected healthspan and personal goals.

Thought leadership and ecosystem building – Co‑create thought‑leadership platforms including research, client forums and CEO‑level dialogues in Hong Kong and other regional hubs to advance understanding of the economics of a 100‑year life, positioning Hong Kong at the forefront of longevity‑driven innovation.

These pillars provide a structured roadmap for turning the idea of “longevity as an asset” into practical offerings and experiences for clients across Asia.

“Humansa was founded on a simple belief: in a 100‑year life, healthspan is the most under‑managed asset on the family balance sheet,” said Don So, Chief Executive Officer of Humansa. “By joining forces with HSBC and HSBC Life, we are building the infrastructure that clients need to measure, protect and grow that asset – with clinical rigour, personalised programs and experiences that match the sophistication of their financial lives.

“Health, wealth and protection are deeply interconnected and shouldn’t be treated in isolation. As people live longer and spend more years beyond working life, they need trusted solutions to protect, grow and pass on their wealth — especially in an increasingly uncertain macro environment. Our partnership with Humansa brings together the best of both organisations to offer high net worth customers a seamless, one-stop health and wealth management solution.” said Daisy Tsang, Chief Executive Officer, HSBC Life Hong Kong and Macau.

“People are living longer, and that changes what ‘wealth planning’ really means. Our partnership with Humansa will help our clients treat healthspan as a core family asset, alongside their financial wealth, so they can stay well, stay active and keep their options open over a longer life. By combining Humansa’s longevity expertise with HSBC’s wealth capabilities, we’ll explore new ways to deliver a premium client experience that supports wellbeing and long-term resilience, setting a new standard for how high‑net‑worth families live well across generations.” said Brian Hui, Chief Customer Officer, Retail Banking and Wealth Management, HSBC Hong Kong.
Hashtag: #Humansa

The issuer is solely responsible for the content of this announcement.

About Humansa

Humansa is a leading healthcare and wellness brand dedicated to extending the human healthspan through evidence-based preventative medicine, advanced diagnostics and holistic lifestyle solutions. Founded in 2020 and headquartered in Hong Kong, Humansa operates an extensive network of centres, offering services that span health assessments, medical services, restorative therapies, wellness coaching and skin aesthetics in a refined, hospitality-inspired environment.

About HSBC and HSBC Life

The Hongkong and Shanghai Banking Corporation Limited is the founding member of the HSBC Group and one of the world’s largest banking and financial services organisations, serving customers across Asia and beyond. HSBC Life (International) Limited is a leading life insurance company, offering a comprehensive range of protection and savings solutions to individuals and corporations across the region. Together, they provide integrated banking, wealth and insurance services designed to meet the evolving financial and lifestyle needs of their clients.

By K Raveendran Friday’s twin constitutional dramas exposed two serious threats to Indian democracy: the refusal of a defeated ruler to leave office, and the reluctance of a constitutional referee to invite a claimant who appeared to be assembling the numbers to form a government. Mamata Banerjee’s refusal to resign after the Trinamool Congress lost […]

The article Indian Democracy’s Black Friday: Popular Will Held Hostage By Power And Prejudice appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

By T N Ashok CHENNAI: Tamil Nadu’s political drama entered its most decisive phase on Friday evening as actor-turned-politician C. Joseph Vijay moved within touching distance of forming the State’s next government after the Communist Party of India and the CPI(M) extended unconditional support to his fledgling Tamilaga Vettri Kazhagam. The support of the two […]

The article Instability Stares At Tamil Nadu Polity Even If Vijay Cobbles Up A Majority Of 118 appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).